2025-12-12 ハーバード大学
The personalized biomaterial-based cancer vaccine consists of a porous biomaterial scaffold the size of an aspirin tablet that is infused with immune cell-recruiting and activating molecules and inactivated tumor antigens derived from tumors of the trial participants. Credit: Wyss Institute at Harvard University
<関連情報>
- https://seas.harvard.edu/news/2025/12/clinical-trial-personalized-cancer-vaccine-demonstrates-feasibility-safety-immune
- https://aacrjournals.org/cancerimmunolres/article-abstract/13/7/978/763129/First-in-Human-Clinical-Trial-of-Vaccination-with
転移性黒色腫患者を対象とした、自己腫瘍細胞溶解液を含む樹状細胞活性化スキャフォールドWDVAXを用いたワクチン接種のヒト初臨床試験 First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
F. Stephen HodiCorresponding Author;Anita Giobbie-Hurder;Kwasi Adu-Berchie;Srin Ranasinghe;Ana Lako;Mariano Severgnini;Emily M. Thrash;Jason L. Weirather;Joanna Baginska;Michael P. Manos;Edward J. Doherty;Alexander Stafford;Heather Daley;Jerome Ritz;Patrick A. Ott;Kathleen L. Pfaff;Scott J. Rodig;Charles H. Yoon;Glenn Dranoff;David J. Mooney
Cancer Immunology Research Published:July 02 2025
DOI:https://doi.org/10.1158/2326-6066.CIR-24-0333
Abstract
The optimal means to prime for effective antitumor immunity in a patient with cancer remain elusive in the current era of checkpoint blockade. Crafting a strategy to amplify the number and function of CD8+ T cells while blocking regulatory cells should increase immunotherapy efficacy. Biomaterial carriers have been demonstrated in preclinical studies to amplify the effects of immunomodulatory agents, synergistically integrate the effects of different agents, and concentrate and manipulate immune cells in vivo. Herein, we report data from a phase I trial in patients with metastatic melanoma who received the cytokine GM-CSF and the innate Toll-like receptor 9 agonist CpG oligonucleotide admixed with autologous tumor lysate onto a microporous poly-lactide-co-glycolide matrix polymer scaffold that achieves precise control over the spatial and temporal release of immunostimulatory agents in vivo. This materials system (WDVAX) served as a physical antigen-presenting structure to which dendritic cells and other immune-stimulating cells are recruited and activated. In this first clinical trial of a macroscale biomaterial–based vaccine, WDVAX treatment was found to be feasible and to induce immune activation in patients with melanoma.
